StreetAlpha.app
Home › Stocks › ALVO

Alvotech (ALVO)

Healthcare
$4.12
▼ −3.96%
LAST CLOSE · NOV 20

Alvotech develops and manufactures biosimilar medicines, sold through pharmaceutical partners to patients worldwide. It last closed at $4.12 on Nov 20, down 3.96% on the day.

AI Auto Pilots
Is ALVO in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ALVO.

Key Stats

Last 12 months
Results
Revenue
$586.3M
+19.7% vs a year ago
Net income
$27.9M
4.8% margin
Free cash flow
−$114.7M
−19.6% margin
Operating margin
13.3%
$78.2M operating income
Balance sheet
Cash & equivalents
$172.4M
At Dec 31
Debt
$1.3B
At Dec 31
Shareholder equity
−$284.5M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $36.8M$36.8MFY2021FY2022: $83.0M$83.0MFY2022FY2023: $91.4M$91.4MFY2023FY2024: $489.7M$489.7MFY2024FY2025: $586.3M$586.3MFY2025

From ALVO's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 31). Last 12 months adds up the four latest quarters. Per share figures are left out because the US listing can represent a different number of shares.

Next report
—
No date on the calendar yet
Consensus EPS forecast
EPS and revenue estimates
Year-ago EPS
Same quarter last year
Options-implied move
Move priced in by options
Analyst consensus
Ratings from the last 90 days
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ALVO
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ALVO

Technical Analysis

ALVO · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend, nearing oversold

The stock is 12% below its 20 day and 25% below its 50 day average. It is 1% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 38), near oversold. The nearest support is the Pivot S1 at $4.04, and the nearest resistance the 200 day average at $4.16.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityHigh, 7.5%/day
Key levels
$6.5352 week high+58.5%
$5.1450 day average+24.8%
$4.6020 day average+11.7%
$4.60100 day average+11.7%
$4.24Pivot R1+2.9%
$4.18Swing high (Aug 14)+1.5%
$4.17Pivot+1.2%
$4.16200 day average+1.0%
$4.12Last close
$4.04Pivot S1−1.9%
$3.75Swing low (Aug 20)−9.0%
$2.9452 week low−28.6%
Indicators
RSI (14)37.63Weak, oversold below 30Neutral
MACD-0.21Below its signal lineBearish
Stochastic22.6Middle of its rangeNeutral
ADX (14)17.1No clear trend
Williams %R-96.8Oversold below −80, overbought above −20Oversold
CCI (20)-176.3Oversold below −100, overbought above 100Oversold
Rate of change−15.2%Change over 10 sessionsBearish
ATR (14)$0.31Typical daily range, 7.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ALVO

What happened before

See how ALVO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ALVO usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ALVO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2022.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ALVOHow many large options trades hit ALVO, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

ALVO Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲50 buying vs 23 selling
  • ▲Shares held by funds +21.8%
  • ▲Funds holding +7
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding7972+9.7%
In funds' top 10220.0%
Held by funds–––
New / increased17 / 3322 / 21+16.3%
Reduced / sold out14 / 919 / 7−11.5%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ALVO institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ALVO is in one of them and how their past ALVO trades turned out.

ALVO in the AI portfolios
Loading…

ALVO News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ALVO in an article yet. Here's the latest on the wider market.

ALVO in the news

About Alvotech

Alvotech is a biotechnology company based in Luxembourg that develops and manufactures biosimilars, which are lower cost versions of established biologic medicines. Its approved products copy treatments for conditions such as arthritis, psoriasis, Crohn's disease, macular degeneration and osteoporosis. The company handles research, manufacturing and regulatory work in-house and licenses its products to pharmaceutical partners that sell them in global markets, serving patients worldwide.

Headquarters
Luxembourg, Luxembourg